EyeGate Pharmaceuticals announced it reached 75% enrollment in a pivotal phase 3 clinical trial of EGP-437 for the treatment of noninfectious anterior uveitis.
The double-masked, randomized, positive-controlled trial is designed to assess the safety and efficacy of iontophoretically delivered EGP-437. The trial will enroll 250 subjects in the U.S., according to a company press release.
By achieving 75% enrollment in the trial, EyeGate earned a milestone payment under a licensing agreement with a subsidiary of Valeant Pharmaceuticals.
EGP-437 is a novel formulation of dexamethasone phosphate
Uncategorized